labetalol has been researched along with Cerebrovascular Disorders in 6 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous labetalol is commonly used in the management of hypertensive emergencies or urgencies as well as postoperative hypertension." | 7.67 | The safety of cumulative doses of labetalol in perioperative hypertension. ( Cosentino, F; Little, JR; Orlowski, JP; Shiesley, D; Vidt, DG, 1989) |
| "Intravenous labetalol is commonly used in the management of hypertensive emergencies or urgencies as well as postoperative hypertension." | 3.67 | The safety of cumulative doses of labetalol in perioperative hypertension. ( Cosentino, F; Little, JR; Orlowski, JP; Shiesley, D; Vidt, DG, 1989) |
| " At dosage levels similar to arotinolol, both pindolol and labetalol were less effective in preventing cerebral lesions despite lower blood pressure." | 1.28 | Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP. ( Hara, Y; Maniwa, T; Miyagishi, A; Noguchi, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ram, CV | 2 |
| Patel, RV | 1 |
| Kertland, HR | 1 |
| Jahns, BE | 1 |
| Zarowitz, BJ | 1 |
| Mlynarek, ME | 1 |
| Fagan, SC | 1 |
| Trejo Gabriel y Galán, JM | 1 |
| Miyagishi, A | 1 |
| Maniwa, T | 1 |
| Noguchi, T | 1 |
| Hara, Y | 1 |
| Cosentino, F | 1 |
| Vidt, DG | 1 |
| Orlowski, JP | 1 |
| Shiesley, D | 1 |
| Little, JR | 1 |
| Meese, RB | 1 |
3 reviews available for labetalol and Cerebrovascular Disorders
| Article | Year |
|---|---|
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
[Treatment of medical complications: hypertension/hypotension, hyperglycemia, hyperthermia, hypoxia, cardiac complications and pulmonary embolism].
Topics: Administration, Oral; Antihypertensive Agents; Arrhythmias, Cardiac; Cerebrovascular Disorders; Hear | 1995 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
1 trial available for labetalol and Cerebrovascular Disorders
| Article | Year |
|---|---|
Labetalol: response and safety in critically ill hemorrhagic stroke patients.
Topics: Adult; Aged; Blood Pressure; Cerebral Hemorrhage; Cerebrovascular Disorders; Critical Illness; Femal | 1993 |
2 other studies available for labetalol and Cerebrovascular Disorders
| Article | Year |
|---|---|
Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Brain; Cerebrovascular Disorders; Disease Susc | 1991 |
The safety of cumulative doses of labetalol in perioperative hypertension.
Topics: Adult; Cerebrovascular Disorders; Female; Heart Rate; Hemodynamics; Humans; Hypertension; Infusions, | 1989 |